ASBMR 2019 Archives

ASBMR 2019

Reduced Mobility From Bone Bridge Formation Affects Low BMD in Ankylosing Spondylitis

By

September 25, 2019

Researchers conducted this study to determine whether bone bridge formation was correlated with low bone mineral density in patients with ankylosing spondylitis.

ASBMR 2019

TNFi Therapy Affects Osteogenic Factors in Axial Spondyloarthritis

By

Rheumatology Advisor Contributing Writer

September 24, 2019

Researchers assessed serum levels of osteogenic factors and the different regulators of bone formation in patients with early axial spondyloarthritis.

ASBMR 2019

Patient Characteristics Predict BMD Response to Bisphosphonates After Denosumab Cessation

By

Amit Akirov, MD

September 24, 2019

Patients with greater BMD improvement after 1 year of denosumab are more likely to lose BMD after the transition to alendronate therapy in the second year.

ASBMR 2019

Positive Patient Experience With Abaloparatide in Osteoporosis

By

Dibash Kumar Das, PhD

September 24, 2019

The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.

Patients with RA experience localized and generalized bone loss.2 Data have also shown that patients with well-controlled RA have significantly more bone loss than healthy individuals.4 The pathology of bone loss in RA is multifactorial and complex. The pannus, a proliferation of inflamed synovial tissue, releases several proinflammatory cytokines. Some, such as TNF-α, IL-1, IL-6, and IL-17, are osteoclastogenic and promote bone resorption, partly through upregulation of nuclear factor-kB ligand.1,3,5 They also inhibit anti-osteoclastogenic cytokines.1 Further, TNF-α upregulates proteins that inhibit the Wnt pathway, thus suppressing osteoblast activity.1,3,5 The resulting imbalance in bone remodeling, favoring bone resorption, causes bone loss and inferior bone quality. Immobility and glucocorticoid use, both common in patients with RA, also promote bone loss.1,2 Standard risk factors for bone loss may exacerbate RA-induced bone loss.5

ASBMR 2019

Improved Safety Outcomes With Twice-Weekly vs Once-Weekly Teriparatide in Osteoporosis

By

Hannah Dellabella

September 23, 2019

Researchers investigated the safety and efficacy of twice-weekly 28.2 μg teriparatide compared with once-weekly 56.5 μg teriparatide in Japanese patients with osteoporosis.

ASBMR 2019

Novel Application of Zoledronic Acid in Sclerosing Osteomyelitis

By

Rheumatology Advisor Contributing Writer

September 23, 2019

Researchers investigated the case of a patient with sclerosing osteomyelitis who was successfully treated with zoledronic acid.